Skip to main content
Caplight Logo









GramEye

GramEye

Private
IbarakiHealthcare & Life Scienceshttps://grameye.com/

Last Round

Series B

Nov 21, 2025

Total Funding Raised

$6.09M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

GramEye is a medical technology company that develops an AI and robotics solution to automate Gram staining, aiming to facilitate the appropriate use of antimicrobials.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Medical AI, Biotech Equipment, Computer Vision

Business Model

B2B

Customer Profile

Hardware Sales, Hardware + Subscription, Government Contracts

AI Layer

Application

Keywords

automated Gram stainingAI bacterial identificationinfectious disease diagnosticsmedtechantimicrobial resistanceAMRmedical AIdiagnostic AIlab automationmedical devicediagnostic roboticsmicroscopy AIcomputational pathologyclinical workflow automationclinical decision support systemCDSS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GramEye Comparables

Compare GramEye with similar companies based on industry and business-model similarity.

GramEye comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Neomend
71%
bioMérieux
70%
Bruker
69%

GramEye Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BNov 21, 2025
Series AOct 13, 2023

Key People

Founding team and executive leadership

Yu Hiraoka

CEO

Executive Team

Ryo Matsukage

CTO AI Development Group Manager

Executive Team

Yamada Tatsuya

COO

Executive Team

GramEye Investors

Notable investors and investment history

GramEye investors
InvestorRounds
DEEPCORE Inc.Series A
Ikeda Senshu CapitalSeries A
Samurai Incubate Inc.Series A, Series B
NES Inc.Series A, Series B
Beyond Next VenturesSeries B
STATION Ai CorporationSeries A
SMBC Venture CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors grew 46% MoM, reaching 6K.

  • Apr 18, 2026

    Monthly visitors increased 55% MoM.

GramEye Filings

Explore SEC and related filing metadata, where available.

GramEye filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about GramEye's valuation, stock price, and market status.

Is GramEye a public or private company?

GramEye is a private company.

What is the current stock price of GramEye?

GramEye is a private company with no public stock price. No recent secondary market data is available.

How much is GramEye worth (valuation)?

Valuation information for GramEye is not publicly available.

Can I buy GramEye stock?

GramEye shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was GramEye's last funding round?

GramEye's most recent funding round was Series B on November 21, 2025.

Who are the main investors in GramEye?

Key investors in GramEye include Beyond Next Ventures.

Will GramEye IPO soon?

No public IPO plans have been announced for GramEye.

How can I track GramEye secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor GramEye's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersIbaraki
Employee Range5
Year Founded2020
Last FundingNov 21, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?